

| Key Words | Patient group | Treatment | Patient Criteria |
|---|---|---|---|
| JUNO BCMA CAR-T | - at least 3 prior lines including daratumumab | CAR-T cells after lympho depletion | Fit patients with advanced disease |
| CC99712 BCMA antibody drug conjugate | - at least 3 prior lines including daratumumab | Infusion of CC99712 every 3 weeks | Less fit patients with advanced disease |
| Survivin vaccine | - newly diagnosed multiple myeloma - at least a partial response after induction - receiving lenalidomide maintenance | Injection of surviving vaccine in addition to lenalidomide maintenance | Non-transplant eligible patients after induction |
| Abatacept/ Ixazomib/ Dex | - relapsed after ONE proteasome inhibitor (PI) and not been treated with a second PI | Abatacept weekly s.c. Ixazomib weekly oral Dex weekly oral | Slow progressing patients at first relapse |
| Ixazomib/ Pomalidomide/ Dexamethasone | - progressing on lenalidomide as first line treatment | Ixazomib weekly Pomalidomide d1-21 Dex weekly Versus Pomalidomide/Dex alone | Patients who want all oral treatment at first relapse |
| PLANNED | | | |
| DaraKRD upfront Spring 2020 | Newly diagnosed myeloma | DaraKRD versus KRD versus VRD | All untreated newcomers |
| Janssen BCMA CAR-T cells Spring 2020 | <u>Cohort A</u> 1-3 prior lines incl PI and IMiD <u>Cohort B</u> 1 st relapse < 12 months from start of treatment | CAR-T cells after lympho depletion | Fit patients with early progression disease or otherwise aggressive disease |
| BCMA antibody drug conjugate expanded access program February 2020 | - at least 3 prior lines incl. daratumumab | Belantamab Mafodotin every 3 weeks | Heavily pretreated patient not eligible for CAR-T or BCMA study |